Protocols
4 protocol(s) meet the specified criteria
Drug: PS-341
Protocol No.TitleStatus
54767414MMY2004Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell TransplantationOpen
CALGB50403A Randomized Phase II Trial of Maintenance vs Consolidation Bortezomib Therapy Following Aggresive Chemo-Immunotherapy and Autologous Stem Cell Transplant for Previously Untreated Mantle Cell LymphomaOpen (affiliates only)
CALGB50904A Randomized Phase II Trial of Ofatumumab and Bendamustine Vs. Ofatumumab, Bortezomib (NSC #681239, IND #58443) and Bendamustine in Patients with Untreated Follicular Lymphoma Open (affiliates only)
COGAAML1031A Phase III Randomized Trial for Patients with de novo AML using Bortezomib(IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITDOpen